IHH subsidiary sues Japanese pharma company over Fortis Malar deal

The IHH unit is seeking to claim damages of JPY20b from the Japanese company.

Northern TK Venture, an indirect wholly owned subsidiary of IHH Healthcare, has filed a lawsuit against Japanese pharmaceutical company, Daiichi Sankyo for allegedly preventing them from proceeding with open offers to buy a stake at India’s Fortis Healthcare.

In a bourse filing, SGX-listed IHH Healthcare said its subsidiary filed a JPY20b claim against Daiichi Sankyo at the Tokyo District Court for causing losses to the former.

Under the lawsuit filed by NTK, Daiichi Sankyo will have to pay JPY20b with interest of 3% per annum.

“NTK is also seeking an injunction to prevent Daiichi Sankyo from making defamatory remarks against NTK concerning the open offers,” IHH Healthcare stated.

“The claims filed by NTK against Daiichi Sankyo are tort claims premised on the latter’s unlawful interference with NTK’s trade or business, conspiracy of Daiichi Sankyo and other persons, malicious falsehood and defamation under the applicable substantive laws,” the company added.

Follow the link for more news on

IHH Healthcare

Also Read

Secondhand furniture gains traction as Singaporeans embrace circular economy practices

Agilent partners with NUS to advance cardiovascular research in Singapore

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit

Top News

SBR 5 Lorem Ipsum News 2 [8 May]

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

6 days ago

SBR 4 Lorem Ipsum [8 May Top Stories]

6 days ago

Vibrant Group wins suit against Blackgold Australia

The group shall be paid damages and fees by Blackgold Australia’s ex-CEO and ex-chairman.

Lorem Ipsum text in year 2025

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.

Agribusiness